Press release
Carcinoid Syndrome Diarrhea Treatment Market
According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1216
Major key players operating in the carcinoid syndrome diarrhea treatment market include Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, and BTG International Ltd.
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and asthma. For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid are asymptomatic until the tumor is fully developed. To overcome the carcinoid crisis, treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. Carcinoid syndrome being a rare condition, there are very few if any treatment options available. This in turn, creates a highly lucrative opportunities for market players.
Novel ground-breaking therapy to provide immense opportunities for market growth
In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analogue rescue therapy.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1216
Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Carcinoid Syndrome Diarrhea Treatment Market here
News-ID: 1036774 • Views: …
More Releases from Pharmaceutical Report
Pharmaceutical Robots Market Forecast 2018- 2026: Kawasaki Heavy Industries,
Kawasaki Heavy Industries Ltd. (Japan), FANUC Corporation (Japan), KUKA AG (Germany), Mitsubishi Electric Corporation (Japan), ABB Ltd. (Switzerland), Denso Corporation (Japan), Seiko Epson Corporation (Japan), Marchesini Group S.p.A (Italy), Universal Robots A/S (Denmark), Kawasaki Heavy Industries ,Yaskawa Electric Corporation (Japan), and Shibuya Corporation (Japan) are the prominent players in the global pharmaceutical robots market.
The global pharmaceutical robots market is anticipated to reach 452.7 million by 2025 and estimated to reach…
Grow Owning to Innovations In Oncology Nutrition Market
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
FMD Vaccine Market - Shield against Economic Loss
Foot and Mouth Disease (FMD) causes repetitive outbreak around world thereby causing economic and social damage. Preventing foot and mouth disease is the only sustainable and viable options, which can be done only though the vaccination for FMD, which is expected to drive growth of the foot and mouth disease vaccine market. According to paper published by the Food and Agricultural Organization (FAO) and World Organization for Animal Health (OIE),…
Divalproex Sodium Market Competitive Landscape,Regional Insights
Increasing prevalence of bipolar disorders around the globe is propelling the divalproex sodium market growth. For instance, according to study published in JAMA Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11 countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and 0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%, yielding a total prevalence estimates bipolar disorder spectrum of 2.4% globally.
Moreover, rising patient pool…
More Releases for Carcinoid
Carcinoid Syndrome Diarrhea Treatment Market - Increasing prevalence of rare car …
Carcinoid Syndrome Diarrhea Treatment Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Carcinoid Syndrome Diarrhea Treatment Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor…
Carcinoid Syndrome Diarrhea Treatment Market Size, Status and Forecast To
Carcinoid Syndrome Diarrhea Treatment Market
The Global Carcinoid Syndrome Diarrhea Treatment Market research report provides a unique methodology for evaluating the market insights, highlighting opportunities and supporting strategic and tactical decision-making. This report recognizes the requirement of a rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on the latest trends and developments and focuses on innovations…
Carcinoid Syndrome Management Market to Witness Exponential Growth by 2027
Carcinoid syndrome comprises of signs and symptoms such as flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are developed secondary to carcinoid tumor. The term ‘carcinoid crisis’ is used when all the symptoms of carcinoid syndrome show at a time. Carcinoid tumors arise out of neuroendocrine cells which are present all over the human…
Carcinoid Syndrome Management Market Challenges and Opportunities Report 2017-20 …
Carcinoid syndrome comprises of signs and symptoms such as flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are developed secondary to carcinoid tumor. The term ‘carcinoid crisis’ is used when all the symptoms of carcinoid syndrome show at a time. Carcinoid tumors arise out of neuroendocrine cells which are present all over the human…
Carcinoid Syndrome Diarrhea Treatment Market
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations,…
Carcinoid Syndrome Management Market : Information and Analytical Insights
Carcinoid syndrome comprises of signs and symptoms such as flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are developed secondary to carcinoid tumor. The term ‘carcinoid crisis’ is used when all the symptoms of carcinoid syndrome show at a time. Carcinoid tumors arise out of neuroendocrine cells which are present all over the human…
